169 related articles for article (PubMed ID: 19308670)
1. Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy.
Yano S; Moseley K; Pavlova Z
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S53-7. PubMed ID: 19308670
[TBL] [Abstract][Full Text] [Related]
2. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I.
Braunlin EA; Berry JM; Whitley CB
Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035
[TBL] [Abstract][Full Text] [Related]
3. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
4. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
[TBL] [Abstract][Full Text] [Related]
5. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
7. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
9. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
10. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
[No Abstract] [Full Text] [Related]
11. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
[TBL] [Abstract][Full Text] [Related]
12. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
Thomas JA; Jacobs S; Kierstein J; Van Hove J
J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of severe heart failure in an infant with Hurler syndrome.
Hirth A; Berg A; Greve G
J Inherit Metab Dis; 2007 Oct; 30(5):820. PubMed ID: 17768668
[TBL] [Abstract][Full Text] [Related]
14. Progression of organ manifestations upon enzyme replacement therapy in a patient with mucopolysaccharidosis type I/Hurler.
Mercimek-Mahmutoglu S; Reilly C; Human D; Waters PJ; Stoeckler-Ipsiroglu S
World J Pediatr; 2009 Nov; 5(4):319-21. PubMed ID: 19911152
[TBL] [Abstract][Full Text] [Related]
15. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
[TBL] [Abstract][Full Text] [Related]
16. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
18. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
Illsinger S; Lücke T; Hartmann H; Mengel E; Müller-Forell W; Donnerstag F; Das AM
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S321-5. PubMed ID: 19894140
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
20. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome.
Braunlin E; Mackey-Bojack S; Panoskaltsis-Mortari A; Berry JM; McElmurry RT; Riddle M; Sun LY; Clarke LA; Tolar J; Blazar BR
Pediatr Res; 2006 Jan; 59(1):27-32. PubMed ID: 16326988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
